Literature DB >> 22771878

Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.

Valencia King1, Shari B Goldfarb, Jennifer D Brooks, Janice S Sung, Benjamin F Nulsen, Jolanta E Jozefara, Malcolm C Pike, Maura N Dickler, Elizabeth A Morris.   

Abstract

PURPOSE: To evaluate whether treatment with an aromatase inhibitor (AI) influences background parenchymal enhancement (BPE) or amount of fibroglandular tissue (FGT) at breast magnetic resonance (MR) imaging in postmenopausal women with prior history of breast cancer.
MATERIALS AND METHODS: A waiver of authorization and patient consent was granted by the institutional review board for this HIPAA-compliant retrospective study. Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149). Two readers performed blinded side-by-side comparison of BPE and MR imaging-depicted FGT before and during treatment. BPE and FGT were classified as the same or greater on one of the two MR studies and by using categorical scales: minimal, mild, moderate, or marked for BPE and fatty, scattered, heterogeneously dense, or dense for FGT. Consensus was reached in cases of disagreement. The sign test was used to conduct a side-by-side comparison of BPE and FGT before and during AI treatment.
RESULTS: A decrease in BPE occurred in 33.9% (37 of 109) of women during anastrozole treatment, while an increase occurred in only one (P < .0001); 28 of 37 decreases resulted in a category change of BPE. A decrease in MR imaging-depicted FGT occurred in 5.5% (six of 109) of women, while no increases occurred (P = .031). During letrozole treatment, a decrease in BPE occurred in 46% (15 of 33), while an increase occurred in one woman (P = .0003); a decrease in FGT occurred in only one woman, and no increases occurred. Similar results were seen when women also undergoing chemotherapy were excluded. Only seven women were treated with exemestane.
CONCLUSION: Treatment with 6-12 months of anastrozole or letrozole was associated with decreases in BPE, which occurred in a greater proportion of women than decreases in FGT. © RSNA, 2012

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771878     DOI: 10.1148/radiol.12112669

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Mammographic density, MRI background parenchymal enhancement and breast cancer risk.

Authors:  M C Pike; C L Pearce
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

2.  Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle.

Authors:  Alana R Amarosa; Jason McKellop; Ana Paula Klautau Leite; Melanie Moccaldi; Tess V Clendenen; James S Babb; Anne Zeleniuch-Jacquotte; Linda Moy; Sungheon Kim
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

Review 3.  Evaluation of background parenchymal enhancement on breast MRI: a systematic review.

Authors:  Bianca Bignotti; Alessio Signori; Francesca Valdora; Federica Rossi; Massimo Calabrese; Manuela Durando; Giovanna Mariscotto; Alberto Tagliafico
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

4.  Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.

Authors:  Julie Sogani; Elizabeth A Morris; Jennifer B Kaplan; Donna D'Alessio; Debra Goldman; Chaya S Moskowitz; Maxine S Jochelson
Journal:  Radiology       Date:  2016-07-04       Impact factor: 11.105

5.  Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Authors:  Nola M Hylton; Constantine A Gatsonis; Mark A Rosen; Constance D Lehman; David C Newitt; Savannah C Partridge; Wanda K Bernreuter; Etta D Pisano; Elizabeth A Morris; Paul T Weatherall; Sandra M Polin; Gillian M Newstead; Helga S Marques; Laura J Esserman; Mitchell D Schnall
Journal:  Radiology       Date:  2015-12-01       Impact factor: 11.105

6.  The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancer.

Authors:  Marissa Albert; Freya Schnabel; Jennifer Chun; Shira Schwartz; Jiyon Lee; Ana Paula Klautau Leite; Linda Moy
Journal:  Clin Imaging       Date:  2015-08-06       Impact factor: 1.605

Review 7.  Background parenchymal enhancement on breast MRI: A comprehensive review.

Authors:  Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar
Journal:  J Magn Reson Imaging       Date:  2019-04-19       Impact factor: 4.813

8.  Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.

Authors:  H Preibsch; L Wanner; S D Bahrs; B M Wietek; K C Siegmann-Luz; E Oberlecher; M Hahn; A Staebler; K Nikolaou; B Wiesinger
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

9.  The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.

Authors:  E R Price; J D Brooks; E J Watson; S B Brennan; E A Comen; E A Morris
Journal:  Eur Radiol       Date:  2013-08-28       Impact factor: 5.315

10.  Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.

Authors:  Kimberly M Ray; Karla Kerlikowske; Iryna V Lobach; Michael B Hofmann; Heather I Greenwood; Vignesh A Arasu; Nola M Hylton; Bonnie N Joe
Journal:  Radiology       Date:  2017-10-25       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.